.jpeg)
2026-02-09 05:42:31
Upatinib (Rift) ®） As an oral JAK inhibitor, it has been approved for various immune-mediated inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, etc. The target population is mainly moderate to severe patients, especially suitable for adults who have insufficient response to traditional treatment, need oral convenience, or have poor injection compliance.
2026-02-06 06:18:41
Biktarvy (Bictegravir, Emtricitabine, Tenofovir Disoproxil Fumarate) is a single-tablet, triple-antiretroviral compound containing Bictegravir, Emtricitabine, and Tenofovir Disoproxil Fumarate, which rapidly blocks viral replication through dual inhibition of integrase and reverse transcriptase. The success rate of reducing viral load to the detection limit within 48 hours is over 80%, and the rate of virological failure after 96 weeks of long-term treatment is less than 1%. It has good safety (mainly mild to moderate adverse reactions), significantly improves CD4+ cell count, and is a preferred first-line treatment for HIV-1 infection. It should be used under the guidance of a doctor and in accordance with prescribed standards.
2026-01-15 05:54:14
Celecoxib is a selective COX-2 inhibitor that exerts anti-inflammatory and analgesic effects to relieve the symptoms of cervical spondylosis (such as radiculopathy type and cervical type).
